The fact that β-adrenergic signaling induces neuroendocrine differentiation and apoptosis-resistance of prostate cancer cells suggest that ADRB2 could play a role in predicting responsiveness to pro-apoptotic drugs. The gene discussed is ADRB2; the disease is prostate carcinoma.